Two people who died after donating plasma at for-profit centres in Winnipeg have forced Health Canada and provincial officials to confront an uncomfortable question: when regulators talk about “fatal adverse reactions,” are they thinking first about the human beings in the chair or about the numbers on their safety dashboards? The deaths, reported by CBC and other outlets in March 2026, have exposed how paid plasma schemes can turn low-income donors into line items until tragedy forces a more human accounting.
Health Canada says it has not yet found a direct link between the donation process and either death, and the company operating the centres insists it followed protocol. But families and advocates argue that the official language around the incidents reveals a system that treats donors as data points—especially when they are poor or racialised—until something goes catastrophically wrong.
What happened in Winnipeg’s for-profit plasma centres?
According to detailed reporting by CBC and follow-up coverage from other Canadian outlets, two people died after what Health Canada has described as “fatal adverse reactions” linked to plasma donation at private collection centres in Winnipeg.
- One of the donors was 22-year-old international student Rodiyat Alabede from Nigeria, who collapsed on 25 October 2025 while giving plasma at a Grifols centre on Taylor Avenue and later died in hospital.
- A second death occurred on 30 January 2026 at another Winnipeg plasma clinic, also operated by Grifols, though fewer personal details have been released publicly.
- Both centres are part of a for-profit network that pays donors for plasma, which is later processed into therapies sold on global markets.
- Health Canada has confirmed it received reports of the deaths and is investigating, but has so far said no causal link has been established between the donations and the outcomes.
The company has stated that it followed all required procedures and has no evidence the deaths were caused by plasma donation. For many Winnipeggers, that response sits uneasily beside the basic fact that both individuals died shortly after being hooked up to machines designed to extract a portion of their blood for profit.
How do paid plasma systems turn donors into data points?
Canada’s plasma system now straddles two models: voluntary, unpaid donations collected by Canadian Blood Services, and paid donations at private centres that sell into the pharmaceutical supply chain. Winnipeg has become a focal point of the latter, attracting people who rely on donor fees to cover rent or tuition.
- Donors at for-profit clinics often give far more frequently than voluntary donors, raising questions about long-term health impacts that are difficult to track.
- Health risks and side effects are recorded in regulatory databases as “adverse events,” a necessary but clinical way of abstracting harm.
- In practice, low-income and racialised donors are overrepresented among those who take on the physical risk in exchange for cash payments.
- When something goes wrong, official statements can be quick to emphasise statistical rarity rather than individual stories.
In the Winnipeg cases, Health Canada and Grifols both stressed that deaths after plasma donation are extremely rare and that investigations are ongoing. For families and advocates, the language underscores a deeper problem: a system oriented around throughput and supply security rather than around the lived experience of people in the chair.
What is Health Canada investigating, and what are the limits of the review?
Health Canada has launched a review into both deaths, examining medical records, clinic protocols and any underlying health conditions. The regulator has said its experts will look at whether staff followed required emergency procedures and whether there are systemic issues at the Winnipeg centres.
- The agency has not suspended operations at the clinics, arguing that there is no evidence of an ongoing safety threat.
- Officials emphasise that plasma donation generally carries a low risk when screening and monitoring are done properly.
- Advocates counter that “low risk” at the population level still leaves individual donors bearing 100 percent of the danger if something goes wrong.
- Because the centres are for-profit, any regulatory tightening could have financial implications for the operator and for Canada’s place in the global plasma market.
Those tensions shape the questions Health Canada is willing to ask. Is the problem limited to two tragic anomalies in an otherwise safe system? Or do the deaths reveal blind spots in how regulators account for the cumulative burden placed on donors who treat plasma as income rather than altruism?
How are Manitoba and the public responding?
The political reaction has been cautious but telling. Manitoba Health Minister Uzoma Asagwara has said banning paid plasma in the province is “an option on the table,” even as the government waits for Health Canada’s final findings. Advocacy groups like BloodWatch.org, which oppose for-profit plasma collection, argue that the deaths show why Canada should stick to voluntary, non-commercial donation.
- Some donors interviewed by local media said they fear losing a vital source of income if clinics are shut down, highlighting the economic pressures that drew them to paid plasma in the first place.
- Others expressed anger that they were not fully informed about past adverse events when deciding whether to donate.
- The debate has reopened earlier national arguments about whether paid plasma undermines the voluntary blood system and exploits financial vulnerability.
- Regulators now face pressure to balance safety, supply security and economic realities more transparently.
For many observers, the key question is not only whether Winnipeg’s clinics followed existing rules, but whether those rules were designed with donors’ lives—rather than plasma volumes—as the primary metric of success.
What does this controversy reveal about the body economy?
The Winnipeg deaths sit within a larger global trend in which blood, plasma and other bodily materials are folded into what scholars call the “body economy.” Pharmaceutical companies rely on a steady stream of biological inputs, and regulators are tasked with ensuring both supply and safety in a world where those inputs increasingly come from people paid to participate.
- Plasma-derived medicines are life-saving for many patients, creating strong pressure to keep collection volumes high.
- At the same time, the source of that plasma is often a pool of financially stressed donors who trade short-term income for long-term unknowns.
- Regulatory frameworks tend to highlight aggregate safety statistics and supply resilience, not the structural reasons people feel compelled to sell part of their blood.
- When tragedies occur, the conversation can narrow to whether protocols were followed, rather than whether the underlying economic model is ethical.
Winnipeg’s experience suggests that as Canada leans further into commercial plasma collection, it will need to decide whether donors are treated as full patients—with robust protections and informed consent—or as data points whose stories only surface in rare investigative reports.
Sources
- CBC: 2 people die after ‘fatal adverse reactions’ while giving plasma in Winnipeg
- CBC video: Health Canada reviewing deaths of two plasma donors in Winnipeg
- CityNews: Two Winnipeggers dead after donating plasma; Health Canada says no link so far
- The Globe and Mail: Health Canada reviewing deaths of two people who donated plasma at private centres
- Winnipeg Free Press: Paid plasma donors fear province will stop cash flow after deaths